NCT06480097Active, not recruiting
Bidirectional Cohort Study on Improvement of Quality of Life in Patients After Coronary Intervention With Kuanxiong Aerosol
Source: ClinicalTrials.gov · Last updated 6 Aug 2025
Brief summary (registry, in English)
The goal of this observational study is to compare in patients with Angina Pectoris after PCI for Coronary Heart Disease. The main questions it aims to answer are: * To evaluate the effect of Kuanxiong Aerosol on the quality of life of patients with angina pectoris after PCI for Coronary Heart Disease. * To evaluate the effect of Kuanxiong Aerosol on relieving angina pectoris and improving cardiac function. The comparison group will received routine treatment .The experimental group will received sublingual spray of Kuanxiong Aerosol on the basis of routine treatment，two sprays per time，three times a day, for a continuous month. After 1 month of treatment, the quality of life, the improvement of cardiac function and the relief of angina pectoris were compared between the two groups. Researchers will compare two groups to see if Kuanxiong Aerosol can improve the quality of life, cardiac function, and reduce the frequency and duration of angina pectoris in patients with angina pectoris after PCI.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 4 Jun 2024
- Start date
- 1 Jan 2019
- Primary completion date
- 28 Jul 2025
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- Coronary artery disease
- NCT number
- NCT06480097
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Jan 2019 to the primary completion date, 28 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergic to ingredients contained in Kuanxiong Aerosol
- Blood lipid and uric acid exceeding 1.5 times the upper limit of normal reference value; Uncontrolled severe hypertension with systolic blood pressure \>180mmHg and/or diastolic blood pressure \>110mmHg
- Malignant tumors
- Severe arrhythmias (such as rapid atrial fibrillation, ventricular tachycardia, high atrioventricular block, etc.)
Lab values
- severe hepatic and renal insufficiency (ALT, AST or TBIL\>1.5 times the upper limit of normal reference value, Cr \>1.5 times the upper limit of normal reference value)
Other
- Coronary artery bypass grafting was prepared during the trial
- Women who are pregnant or trying to become pregnant
- The researcher judged that it is not suitable to participate in this study
Who the study is looking for
- Meet the diagnostic criteria for coronary heart disease
- Age 18\~80 years old, male and female, lower limbs can move freely
- Patients with coronary angiography or coronary CT angiography indicating that the rate of coronary artery large vessel stenosis is greater than 80%
- Patients with angina pectoris (angina pectoris frequency ≥3 times/week) after PCI according to the judgment of the treating physician
- According to the doctor\'s judgment, patients who need to use conventional drugs (ACEI/ARB, β-blockers), and patients who need to use Kuanxiong Aerosol drugs on the basis of conventional drug therapy
- Patients voluntarily sign informed consent
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanfang Hospital, Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.